---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-076346"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T14:42:28.658688+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cellectar presents iopofosine I 131 MM data: 32% ORR at optimal dose >60 mCi TAD

## Summary
- Overall response rate 23% in 64 evaluable patients; 32% ORR at optimal >60 mCi TAD dose.
- Clinical benefit rate 75% and disease control rate 85.7% at >60 mCi TAD.
- Triple-class refractory patients achieved 46% ORR (median PFS 3.4 mo); quad-class 50% ORR.
- Grade 3/4 cytopenias common (62.5% thrombocytopenia, anemia, neutropenia); no off-target toxicities.
- Drug given as four 15-min IV infusions over 3 months with low-dose dexamethasone.

## SEC filing metadata
- accession: 0001104659-23-076346
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465923076346/0001104659-23-076346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465923076346/tm2320208d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-076346
- JSON: https://secwatch.observer/filing/0001104659-23-076346.json
- Plain text: https://secwatch.observer/filing/0001104659-23-076346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.